Gérontopôle de Toulouse, IHU HealthAge, Institut du Vieillissement, Centre Hospitalo-Universitaire de Toulouse, Toulouse, France.
CERPOP UMR 1295, University of Toulouse III, Inserm, UPS, Toulouse, France.
Nat Commun. 2023 Aug 19;14(1):5038. doi: 10.1038/s41467-023-39786-7.
Geroscience is becoming a major hope for preventing age-related diseases and loss of function by targeting biological mechanisms of aging. This unprecedented paradigm shift requires optimizing the design of future clinical studies related to aging in humans. Researchers will face a number of challenges, including ideal populations to study, which lifestyle and Gerotherapeutic interventions to test initially, selecting key primary and secondary outcomes of such clinical trials, and which age-related biomarkers are most valuable for both selecting interventions and predicting or monitoring clinical responses ("Gerodiagnostics"). This article reports the main results of a Task Force of experts in Geroscience.
衰老科学正成为通过靶向衰老的生物学机制来预防与年龄相关的疾病和功能丧失的主要希望。这种前所未有的范式转变需要优化与人类衰老相关的未来临床研究的设计。研究人员将面临许多挑战,包括研究的理想人群、最初要测试的生活方式和衰老干预措施、选择此类临床试验的关键主要和次要结果,以及哪些与年龄相关的生物标志物对于选择干预措施以及预测或监测临床反应(“衰老诊断学”)最有价值。本文报告了衰老科学专家工作组的主要结果。